These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 30321186)

  • 1. Stimulation of natural killer cells with rhCD137 ligand enhances tumor-targeting antibody efficacy in gastric cancer.
    Misumi T; Tanabe K; Fujikuni N; Ohdan H
    PLoS One; 2018; 13(10):e0204880. PubMed ID: 30321186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer.
    Srivastava RM; Trivedi S; Concha-Benavente F; Gibson SP; Reeder C; Ferrone S; Ferris RL
    Clin Cancer Res; 2017 Feb; 23(3):707-716. PubMed ID: 27496866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-CD137 monoclonal antibody enhances trastuzumab-induced, natural killer cell-mediated cytotoxicity against pancreatic cancer cell lines with low human epidermal growth factor-like receptor 2 expression.
    Masu T; Atsukawa M; Nakatsuka K; Shimizu M; Miura D; Arai T; Harimoto H; Kondo C; Kaneko K; Futagami S; Kawamoto C; Takahashi H; Iwakiri K
    PLoS One; 2018; 13(12):e0200664. PubMed ID: 30596643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer.
    Kohrt HE; Houot R; Weiskopf K; Goldstein MJ; Scheeren F; Czerwinski D; Colevas AD; Weng WK; Clarke MF; Carlson RW; Stockdale FE; Mollick JA; Chen L; Levy R
    J Clin Invest; 2012 Mar; 122(3):1066-75. PubMed ID: 22326955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Canine non-B, non-T NK lymphocytes have a potential antibody-dependent cellular cytotoxicity function against antibody-coated tumor cells.
    Kim Y; Lee SH; Kim CJ; Lee JJ; Yu D; Ahn S; Shin DJ; Kim SK
    BMC Vet Res; 2019 Oct; 15(1):339. PubMed ID: 31610784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting CD137 enhances the efficacy of cetuximab.
    Kohrt HE; Colevas AD; Houot R; Weiskopf K; Goldstein MJ; Lund P; Mueller A; Sagiv-Barfi I; Marabelle A; Lira R; Troutner E; Richards L; Rajapaska A; Hebb J; Chester C; Waller E; Ostashko A; Weng WK; Chen L; Czerwinski D; Fu YX; Sunwoo J; Levy R
    J Clin Invest; 2014 Jun; 124(6):2668-82. PubMed ID: 24837434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines.
    Roda JM; Joshi T; Butchar JP; McAlees JW; Lehman A; Tridandapani S; Carson WE
    Clin Cancer Res; 2007 Nov; 13(21):6419-28. PubMed ID: 17962339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential regulation of human monocytes and NK cells by antibody-opsonized tumors.
    Yin J; Albers AJ; Smith TS; Riddell GT; Richards JO
    Cancer Immunol Immunother; 2018 Aug; 67(8):1239-1250. PubMed ID: 29855696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells.
    Baessler T; Charton JE; Schmiedel BJ; Grünebach F; Krusch M; Wacker A; Rammensee HG; Salih HR
    Blood; 2010 Apr; 115(15):3058-69. PubMed ID: 20008791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation.
    Eitler J; Rackwitz W; Wotschel N; Gudipati V; Murali Shankar N; Sidorenkova A; Huppa JB; Ortiz-Montero P; Opitz C; Künzel SR; Michen S; Temme A; Loureiro LR; Feldmann A; Bachmann M; Boissel L; Klingemann H; Wels WS; Tonn T
    J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38417916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas.
    Rosario M; Liu B; Kong L; Collins LI; Schneider SE; Chen X; Han K; Jeng EK; Rhode PR; Leong JW; Schappe T; Jewell BA; Keppel CR; Shah K; Hess B; Romee R; Piwnica-Worms DR; Cashen AF; Bartlett NL; Wong HC; Fehniger TA
    Clin Cancer Res; 2016 Feb; 22(3):596-608. PubMed ID: 26423796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I clinical trial of adoptive transfer of expanded natural killer cells in combination with IgG1 antibody in patients with gastric or colorectal cancer.
    Ishikawa T; Okayama T; Sakamoto N; Ideno M; Oka K; Enoki T; Mineno J; Yoshida N; Katada K; Kamada K; Uchiyama K; Handa O; Takagi T; Konishi H; Kokura S; Uno K; Naito Y; Itoh Y
    Int J Cancer; 2018 Jun; 142(12):2599-2609. PubMed ID: 29388200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs--rituximab and trastuzumab.
    Tokuyama H; Hagi T; Mattarollo SR; Morley J; Wang Q; So HF; Moriyasu F; Nieda M; Nicol AJ
    Int J Cancer; 2008 Jun; 122(11):2526-34. PubMed ID: 18307255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody.
    Chen Y; You F; Jiang L; Li J; Zhu X; Bao Y; Sun X; Tang X; Meng H; An G; Zhang B; Yang L
    Oncotarget; 2017 Jun; 8(23):37128-37139. PubMed ID: 28415754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
    Mercogliano MF; De Martino M; Venturutti L; Rivas MA; Proietti CJ; Inurrigarro G; Frahm I; Allemand DH; Deza EG; Ares S; Gercovich FG; Guzmán P; Roa JC; Elizalde PV; Schillaci R
    Clin Cancer Res; 2017 Feb; 23(3):636-648. PubMed ID: 27698002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 4-1BB (CD137) ligand enhanced anti-tumor immune response against mouse forestomach carcinoma in vivo.
    Li Q; Ai J; Song Z; Liu J; Shan B
    Cell Mol Immunol; 2008 Oct; 5(5):379-84. PubMed ID: 18954562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro cytotoxic effect of Trastuzumab in combination with Pertuzumab in breast cancer cells is improved by interleukin-2 activated NK cells.
    Asgari A; Sharifzadeh S; Ghaderi A; Hosseini A; Ramezani A
    Mol Biol Rep; 2019 Dec; 46(6):6205-6213. PubMed ID: 31493284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SAHA/Vorinostat induces the expression of the CD137 receptor/ligand system and enhances apoptosis mediated by soluble CD137 receptor in a human breast cancer cell line.
    Bellarosa D; Bressan A; Bigioni M; Parlani M; Maggi CA; Binaschi M
    Int J Oncol; 2012 Oct; 41(4):1486-94. PubMed ID: 22797667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-15 enhances the anti-tumor activity of trastuzumab against breast cancer cells but causes fatal side effects in humanized tumor mice (HTM).
    Wege AK; Weber F; Kroemer A; Ortmann O; Nimmerjahn F; Brockhoff G
    Oncotarget; 2017 Jan; 8(2):2731-2744. PubMed ID: 27835865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of FcγRIIIA effector cells used in in vitro ADCC bioassay: Comparison of primary NK cells with engineered NK-92 and Jurkat T cells.
    Hsieh YT; Aggarwal P; Cirelli D; Gu L; Surowy T; Mozier NM
    J Immunol Methods; 2017 Feb; 441():56-66. PubMed ID: 27939300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.